Twenty-four-month postradiation prostate biopsies are strongly predictive of 7-year disease-free survival

Cancer

Volumn 115, Issue 3, 2009, Pages 673-679

  Crook, Juanita M ^a   Malone, Shawn ^b   Perry, Gad ^b   Eapen, Libni ^b   Owen, Julie ^c   Robertson, Susan ^d   Ludgate, Charles ^e   Fung, Sharon ^a   Lockwood, Gina ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b OTTAWA REGIONAL CANCER CENTRE   (Canada)

^c Northeastern Ontario Regional Cancer Centre   (Canada)

^d UNIVERSITY OF OTTAWA   (Canada)

^e Ottawa Hospital ^*  (Canada)

Author keywords

Neoadjuvant hormone therapy; Postradiation prostate biopsies; Prostate cancer; Radiotherapy

Indexed keywords

FLUTAMIDE; GOSERELIN; TESTOSTERONE;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC VALUE; DISEASE FREE SURVIVAL; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; TESTOSTERONE BLOOD LEVEL;

AGED; AGED, 80 AND OVER; BIOPSY; CANADA; DISEASE-FREE SURVIVAL; FLUTAMIDE; GOSERELIN; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSTATIC NEOPLASMS; RADIOTHERAPY DOSAGE; TREATMENT OUTCOME;

EID: 60049090809     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.24020     Document Type: Article

References (19)

1. Crook JM, Bahadur YA, Robertson SJ, Perry GA, Esche BA. Evaluation of radiation effect, tumor differentiation, and prostate specific antigen staining in sequential prostate biopsies after external beam radiotherapy for patients with prostate carcinoma. Cancer. 1997;79:81-89.
2. Gaudin PB, Zelefsky MJ, Leibel SA, Fuks Z, Reuter VE. Histopathologic effects of 3-dimensional conformal external beam radiation therapy on benign and malignant prostate tissues. Am J Surg Pathol. 1999;23:1021-1031.
3. Crook J, Ludgate L, Malone S, et al. Final report of a multicenter Canadian phase III randomized trial of 3 versus 8 months of neoadjuvant androgen deprivation before conventional-dose radiotherapy for clinically localized prostate cancer. Int J Radiat Oncol Biol Phys. 2009 Aug 14 [Epub ahead of print].
4. Sobin LH, Wittekind C, eds. TNM Classification of Malignant Tumors. 5th ed. New York, NY: John Wiley & Sons; 1997.
5. D'Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998;280:969-974.
6. Crook J, Ludgate C, Malone S, et al. Report of a multicenter Canadian phase III randomized trial of 3 months vs 8 months of neoadjuvant androgen deprivation before standard-dose radiotherapy for clinically localized prostate cancer. Int J Radiat Oncol Biol Phys. 2004;60:15-23.
7. Crook J, Malone S, Perry G, Bahadur Y, Robertson S, Abdolell M. Postradiotherapy prostate biopsies: what do they really mean? Results for 498 patients. Int J Radiat Oncol Biol Phys. 2000;48:355-367.
8. Crook JM, Bahadur YA, Bociek RG, Perry GA, Robertson SJ, Esche BA. Radiotherapy for localized prostate carcinoma. The correlation of pretreatment prostate specific antigen and nadir prostate specific antigen with outcome as assessed by systematic biopsy and serum prostate specific antigen. Cancer. 1997;79:328-336.
9. Roach M, 3rd, Hanks G, Thames H Jr, et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys. 2006; 65:965-974.
10. Kalbfleisch JD, Prentice RL. The Statistical Analysis of Failure Time Data. Hoboken, NJ: John Wiley & Sons; 2002.
11. Pintilie M. Analysing and interpreting competing risk data. Stat Med. 2007;26:1360-1367.
12. Pintilie M. Dealing with competing risks: testing covariates and calculating sample size. Stat Med. 2002;21:3317-3324.
13. Kestin LL, Goldstein NS, Vicini FA, et al. Pathologic evidence of dose-response and dose-volume relationships for prostate cancer treated with combined external beam radiotherapy and high-dose-rate brachytherapy. Int J Radiat Oncol Biol Phys. 2002;54:107-118.
14. Pollack A, Zagars GK, Antolak JA, Kuban DA, Rosen II. Prostate biopsy status and PSA nadir level as early surrogates for treatment failure: analysis of a prostate cancer randomized radiation dose escalation trial. Int J Radiat Oncol Biol Phys. 2002;54:677-685.
15. Vance W, Tucker SL, de Crevoisier R, Kuban DA, Cheung MR. The predictive value of 2-year posttreatment biopsy after prostate cancer radiotherapy for eventual biochemical outcome. Int J Radiat Oncol Biol Phys. 2007;67:828-833.
16. Nichol A, Chung P, Lockwood G, et al. A phase II study of localized prostate cancer treated to 75.6 Gy with 3D conformal radiotherapy. Radiother Oncol. 2005;76:11-17.
17. Zelefsky MJ, Reuter VE, Fuks Z, Scardino P, Shippy A. Influence of local tumor control on distant metastases and cancer related mortality after external beam radiotherapy for prostate cancer. J Urol. 2009;178:1368-1373.
18. Stone NN, Stock RG, White I, Unger P. Patterns of local failure following prostate brachytherapy. J Urol. 2007;177: 1759-1763; discussion 1763-1754.
19. Schmeller NT, Jocham D, Staehler G, Schmiedt E, Davis J, Drach GW. Cytologic regression grading of hormone- treated prostatic cancer. Prostate. 1986;9:1-7.